Author(s): Syafika Alaydrus, Ajeng Diantini, Riezki Amalia, Sriwidodo, Anis Yohana Chaerunisa, Nasrul Wathoni


DOI: 10.52711/0974-360X.2022.00078   

Address: Syafika Alaydrus1,2*, Ajeng Diantini1, Riezki Amalia1, Sriwidodo3, Anis Yohana Chaerunisa3, Nasrul Wathoni3
1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, West Java 45363, Indonesia.
2Department of Pharmacy, STIFA Pelita Mas Palu, Central Sulawesi, Indonesia.
3Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, West Java 45363, Indonesia.
*Corresponding Author

Published In:   Volume - 15,      Issue - 1,     Year - 2022

Cancer has been caused by more death globally and is associated with magnesium and calcium intake with some cancers. Some studies are shown as a protective agent against chemotherapy-induced nephrotoxicity and neurotoxicity. Despite magnesium and calcium are the opposite in inflammation, reabsorption regulation, and other physiological processes. However, it is important to maintain the balance between magnesium and calcium related to the micronutrients' physiological functions. One of the cancer drugs can lead to hypomagnesemia and hypocalcemia electrolytes such as cisplatin. The purpose of this article is to review the cisplatin mechanism in electrolyte disorder and the association between potential magnesium and calcium for therapy of some cancer.

Cite this article:
Syafika Alaydrus, Ajeng Diantini, Riezki Amalia, Sriwidodo, Anis Yohana Chaerunisa, Nasrul Wathoni. The Future Prospective: Potential Magnesium and Calcium for Detracting Side Effect Cisplatin. Research Journal of Pharmacy and Technology. 2022; 15(1):481-8. doi: 10.52711/0974-360X.2022.00078

Syafika Alaydrus, Ajeng Diantini, Riezki Amalia, Sriwidodo, Anis Yohana Chaerunisa, Nasrul Wathoni. The Future Prospective: Potential Magnesium and Calcium for Detracting Side Effect Cisplatin. Research Journal of Pharmacy and Technology. 2022; 15(1):481-8. doi: 10.52711/0974-360X.2022.00078   Available on:

1.    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians. 2018;68(6):394-424.
2.    Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA: a Cancer Journal for Clinicians. 2019;69(5):363-385.
3.    Malvezzi M, Carioli G, Bertuccio P, et al. Reply to the letter to the editor ‘European cancer mortality predictions for the year 2019 with focus on breast cancer, by Malvezzi M et al’by Marsden and Hamoda, On behalf of the British Menopause Society Medical Advisory Council. Annals of Oncology. 2019;30(8):1394-1394.
4.    Castiglioni S, Maier JA. Magnesium and cancer: a dangerous liason. Magnesium Research. 2011;24(3):92-100.
5.    Demir C, Demir H, Esen R, Sehitogullari A, Atmaca M, Alay M. Altered Serum Levels of Elements in Acute Leukemia Cases in Turkey. Asian Pacific Journal of Cancer Prevention : APJCP. 2011;12(12):3471-3474.
6.    Dai Q, Motley S, Smith J, et al. Blood Magnesium, and the Interaction with Calcium, on the Risk of High-Grade Prostate Cancer. PloS one. 2011;6(4):e18237-e18237.
7.    Peterlik M, Cross H. Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology. European Journal of Clinical Nutrition. 2009;63(12):1377-1386.
8.    Tao M-H, Dai Q, Millen A, et al. Associations of intakes of magnesium and calcium and survival among women with breast cancer: Results from Western New York Exposures and Breast Cancer (WEB) Study. American Journal of Cancer Research. 2015;6(1):105-113.
9.    Alfarouk KO, Stock C-M, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell International. 2015;15(1):71.
10.    Karale PA, Karale MA, Utikar MC. Advanced Molecular Targeted Therapy in Breast Cancer. Research Journal of Pharmacology and Pharmacodynamics. 2018;10(1):29-37.
11.    Makimoto A, Matsui M, Chin M, et al. Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: A protocol for a randomized phase 2 trial. Contemporary Clinical Trials Communications. 2019;16:100440.
12.    Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, Dirks JH. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney International. 1985;28(6):914-921.
13.    Mirmalek S, Jangholi E, Jafari M, et al. comparison of in Vitro Cytotoxicity and Apoptogenic Activity of Magnesium Chloride and Cisplatin as Conventional Chemotherapeutic Agents in the MCF-7 Cell Line. Asian Pacific Journal of Cancer Prevention: APJCP. 2016;17(S3):131-134.
14.    Sharma BK. Synthetic and Natural Compounds as Anti-Cancer Agents-A Review. Asian Journal of Research in Chemistry. 2017;10(5):699-707.
15.    Suberu JO, Romero‐Canelón I, Sullivan N, Lapkin AA, Barker GC. Comparative cytotoxicity of artemisinin and cisplatin and their interactions with chlorogenic acids in MCF7 breast cancer cells. ChemMedChem. 2014;9(12):2791-2797.
16.    Lajer H, Kristensen M, Hansen H, Christensen S, Jonassen T, Daugaard G. Magnesium and potassium homeostasis during cisplatin treatment. Cancer Chemotherapy and Pharmacology. 2005;55(3):231-236.
17.    Gröber U, Schmidt J, Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7(9):8199-8226.
18.    Kisters K, Gröber U. Magnesium and thiazide diuretics. Magnesium Research. 2018;31(4):143-145.
19.    Jeroen H. Baaij, de.; Joost, G.; Hoenderop, J.; Rene. JM Bindels. Magnesium in man–implication for health and disease. Physiol Rev. 2015;95(1):1-46.
20.    Mendes P, Bezerra D, Santos L, et al. Magnesium in Breast Cancer: What Is Its Influence on the Progression of This Disease? Biological Trace Element Research. 2017;184(3):334-339.
21.    Cao L, Joshi P, Sumoza D. Renal salt-wasting syndrome in a patient with cisplatin-induced hyponatremia: case report. American Journal of Clinical Oncology. 2002;25(4):344-346.
22.    Gums J. Magnesium in cardiovascular and other disorders. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2004;61:1569-1576.
23.    Günther T. Comment on the number of Mg2+-activated enzymes. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. 2008;21:185-187.
24.    Goltzman D, Mannstadt M, Marcocci C. Physiology of the calcium-parathyroid hormone-vitamin D axis. Vitamin D in Clinical Medicine. Vol 50: Karger Publishers; 2018:1-13.
25.    Vakiti A, Mewawalla P. Malignancy-Related Hypercalcemia. StatPearls [Internet]: StatPearls Publishing; 2019.
26.    Wolf FI, Trapani V. Magnesium and its transporters in cancer: a novel paradigm in tumour development. Clinical Science. 2012;123(7):417-427.
27.    Ryazanova L, Rondon L, Zierler S, et al. TRPM7 is essential for Mg homeostasis in mammals. Nature Communications. 2010;1:109-109.
28.    Woudenberg-Vrenken TE, Sukinta A, Van Der Kemp AW, Bindels RJ, Hoenderop JG. Transient receptor potential melastatin 6 knockout mice are lethal whereas heterozygous deletion results in mild hypomagnesemia. Nephron Physiology. 2011;117(2):p11-p19.
29.    Duan J, Li Z, Li J, et al. Structure of the mammalian TRPM7, a magnesium channel required during embryonic development. Proceedings of the National Academy of Sciences. 2018;115(35):E8201-E8210.
30.    Jin J, Wu L-J, Jun J, et al. The channel kinase, TRPM7, is required for early embryonic development. Proceedings of the National Academy of Sciences. 2012;109(5):E225-E233.
31.    Rondón LJ, Groenestege WMT, Rayssiguier Y, Mazur A. Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2008.
32.    Alexander RT, Hoenderop JG, Bindels RJ. Molecular determinants of magnesium homeostasis: insights from human disease. Journal of the American Society of Nephrology. 2008;19(8):1451-1458.
33.    Chubanov V, Mittermeier L, Gudermann T. Role of kinase-coupled TRP channels in mineral homeostasis. Pharmacology and Therapeutics. 2018;184:159-176.
34.    Chubanov V, Waldegger S, y Schnitzler MM, et al. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. Proceedings of the National Academy of Sciences. 2004;101(9):2894-2899.
35.    Li M, Du J, Jiang J, et al. Molecular determinants of Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. Journal of Biological Chemistry. 2007;282(35):25817-25830.
36.    Voets T, Nilius B, Hoefs S, et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. Journal of Biological Chemistry. 2004;279(1):19-25.
37.    Long S, Romani AM. Role of Cellular Magnesium in human diseases. Austin Journal of Nutrition and Food Sciences. 2014;2(10).
38.    Schlingmann KP, Weber S, Peters M, et al. Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nature Genetics. 2002;31(2):166-170.
39.    Zou Z-G, Rios FJ, Montezano AC, Touyz RM. TRPM7, magnesium, and signaling. International Journal of Molecular Sciences. 2019;20(8):1877.
40.    Schmitz C, Perraud A-L, Johnson C, et al. Regulation of Vertebrate Cellular Mg2+ Homeostasis by TRPM7. Cell. 2003;114:191-200.
41.    Goytain A, Quamme GA. Identification and characterization of a novel mammalian Mg 2+ transporter with channel-like properties. BMC Genomics. 2005;6(1):48.
42.    Ryazanova LV, Rondon LJ, Zierler S, et al. TRPM7 is essential for Mg 2+ homeostasis in mammals. Nature Communications. 2010;1(1):1-9.
43.    Sahni J, Tamura R, Sweet IR, Scharenberg AM. TRPM7 regulates quiescent/proliferative metabolic transitions in lymphocytes. Cell Cycle. 2010;9(17):3565-3574.
44.    Zierler S, Yao G, Zhang Z, et al. Waixenicin A Inhibits Cell Proliferation through Magnesium-dependent Block of Transient Receptor Potential Melastatin 7 (TRPM7) Channels. The Journal of Biological Chemistry. 2011;286:39328-39335.
45.    Hanano T, Hara Y, Shi J, et al. Involvement of TRPM7 in Cell Growth as a Spontaneously Activated Ca2+ Entry Pathway in Human Retinoblastoma Cells. Journal of Pharmacological Sciences. 2004;95(4):403-419.
46.    Yee NS, Zhou W, Liang IC. Transient receptor potential ion channel Trpm7 regulates exocrine pancreatic epithelial proliferation by Mg<sup>2+</sup>-sensitive Socs3a signaling in development and cancer. Disease Models and Mechanisms. 2011;4(2):240 LP-254.
47.    Guilbert A, Gautier M, Dhennin-Duthille I, Haren N, Sevestre H, Ouadid-Ahidouch H. Evidence that TRPM7 is required for breast cancer cell proliferation. American Journal of Physiology. Cell physiology. 2009;297:C493-502.
48.    Kim BJ, Park EJ, Lee JH, Jeon J-H, Kim SJ, So I. Suppression of transient receptor potential melastatin 7 channel induces cell death in gastric cancer. Cancer Science. 2008;99(12):2502-2509.
49.    Jiang J, Li M, Inoue K, Chu X-P, Seeds J, Xiong Z-G. Transient Receptor Potential Melastatin 7 like Current in Human Head and Neck Carcinoma Cells: Role in Cell Proliferation. Cancer Research. 2007;67:10929-10938.
50.    Abed E, Moreau R. Importance of melastatin‐like transient receptor potential 7 and cations (Magnesium, calcium) in human osteoblast‐like cell proliferation. Cell Proliferation. 2007;40(6):849-865.
51.    Gao H, Chen X, Du X, Guan B, Liu Y, Zhang H. EGF enhances the migration of cancer cells by up-regulation of TRPM7. Cell calcium. 2011;50(6):559-568.
52.    Park HS, Hong C, Kim BJ, So I. The pathophysiologic roles of TRPM7 channel. The Korean Journal of Physiology and Pharmacology. 2014;18(1):15-23.
53.    Davis FM, Azimi I, Faville RA, et al. Induction of epithelial–mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene. 2014;33(18):2307.
54.    Desai BN, Krapivinsky G, Navarro B, et al. Cleavage of TRPM7 releases the kinase domain from the ion channel and regulates its participation in Fas-induced apoptosis. Developmental Cell. 2012;22(6):1149-1162.
55.    Faouzi M, Kilch T, Horgen FD, Fleig A, Penner R. The TRPM7 channel kinase regulates store‐operated calcium entry. The Journal of Physiology. 2017;595(10):3165-3180.
56.    Cai N, Bai Z, Nanda V, Runnels LW. Mass spectrometric analysis of TRPM6 and TRPM7 phosphorylation reveals regulatory mechanisms of the channel-kinases. Scientific reports. 2017;7:42739.
57.    Beesetty P, Wieczerzak KB, Gibson JN, et al. Inactivation of TRPM7 kinase in mice results in enlarged spleens, reduced T-cell proliferation and diminished store-operated calcium entry. Scientific Reports. 2018;8(1):1-22.
58.    Roskoski Jr R. Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacological Research. 2015;94:9-25.
59.    Mikoshiba K. IP3 receptor/Ca2+ channel: from discovery to new signaling concepts. Journal of Neurochemistry. 2007;102(5):1426-1446.
60.    Izzedine H, Perazella MA. Adverse kidney effects of epidermal growth factor receptor inhibitors. Nephrology Dialysis Transplantation. 2017;32(7):1089-1097.
61.    Bastidas AC, Deal MS, Steichen JM, Guo Y, Wu J, Taylor SS. Phosphoryl transfer by protein kinase A is captured in a crystal lattice. Journal of the American Chemical Society. 2013;135(12):4788-4798.
62.    Wesselink E, Kok DE, Bours MJ, et al. Vitamin D, magnesium, calcium, and their interaction in relation to colorectal cancer recurrence and all-cause mortality. The American Journal of Clinical Nutrition. 2020;111(5):1007-1017.
63.    Wolf FI, Cittadini AR, Maier JA. Magnesium and tumors: ally or foe? Cancer treatment reviews. 2009;35(4):378-382.
64.    Atoe K, Idemudia J, Eboreime O. Serum Magnesium Levels in Women with Breast Cancer in Benin City, Nigeria. Nigeria Science Domain International. 2014;4(6):723-728.
65.    Wesselink E, Winkels RM, Van Baar H, et al. Dietary intake of magnesium or calcium and chemotherapy-induced peripheral neuropathy in colorectal cancer patients. Nutrients. 2018;10(4):398.
66.    Huang W-Q, Long W-Q, Mo X-F, et al. Direct and indirect associations between dietary magnesium intake and breast cancer risk. Scientific Reports. 2019;9:1-10.
67.    Wark P, Lau R, Norat T, Kampman E. Magnesium intake and colorectal tumor risk: A case-control study and meta-analysis. The American Journal of Clinical Nutrition. 2012;96:622-631.
68.    Dibaba D, Xun P, Yokota K, White E, He K. Magnesium intake and incidence of pancreatic cancer: the VITamins and Lifestyle study. British Journal of Cancer. 2015;113(11):1615-1621.
69.    Yang C-Y, Chiu H-F, Tsai S-S, Cheng M-F, Lin M-C, Sung F-C. Calcium and magnesium in drinking water and risk of death from prostate cancer. Journal of Toxicology and Environmental Health Part A. 2000;60(1):17-26.
70.    Muka T, Kraja B, Ruiter R, et al. Dietary mineral intake and lung cancer risk: the Rotterdam Study. European Journal of Nutrition. 2016;56.
71.    Arunkumar P, Mukund H, Radheshyam N, Belliyappa M. Clinical evaluation of cisplatin induced nephrotoxicity characterized by electrolyte disturbances. Asian Journal of Research in Pharmaceutical Science. 2011;1(4):100-104.
72.    Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. Journal of the American Society of Nephrology. 2005;16(2):452-458.
73.    Blachley JD, HILL JB. Renal and electrolyte disturbances associated with cisplatin. Annals of Internal Medicine. 1981;95(5):628-632.
74.    Hanigan M, Devarajan P. Cisplatin nephrotoxicity: Molecular mechanisms. Cancer Therapy. 2003;1:47-61.
75.    Hoffmann K, Marten A, Lindel K, et al. Major combined electrolyte deficiency during therapy with low-dose Cisplatin, 5-Fluorouracil and Interferon alpha: report on several cases and review of the literature [ISRCTN62866759]. BMC Cancer. 2006;6(1):1-5.
76.    Lajer H, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treatment Reviews. 1999;25(1):47-58.
77.    Ashrafi F, Haghshenas S, Nematbakhsh M, et al. The Role of Magnesium Supplementation in Cisplatin-induced Nephrotoxicity in a Rat Model: No Nephroprotectant Effect. International Journal of Preventive Medicine. 2012;3(9):637-643.
78.    Saito Y, Kobayashi M, Yamada T, et al. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Supportive Care in Cancer. 2017;25(2):481-487.
79.    Arany I, Safirstein RL. Cisplatin nephrotoxicity. Seminars in Nephrology. 2003;23(5):460-464.
80.    Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney International. 2008;73(9):994-1007.
81.    Anvari K, Seylanian TM, Mirsadraei M. Evaluation of intravenous magnesium supplementation as prophylaxis for cisplatin-induced Hypomagnesemia. 2010.
82.    Mohammadianpanah M, Omidvari S, Mosalaei A, Ahmadloo N. Cisplatin-induced hypokalemic paralysis. Clinical Therapeutics. 2004;26(8):1320-1323.
83.    Vincenzi B, Santini D, Tonini G. Biological interaction between anti-epidermal growth factor receptor agent cetuximab and magnesium. Expert Opinion on Pharmacotherapy. 2008;9(8):1267-1269.
84.    Maliakal P, Ledford A. Electrolyte and protein imbalance following anti-EGFR therapy in cancer patients: A comparative study. ExpErimEntal and thErapEutic mEdicinE. 2010;1(2):307-311.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

56th percentile
Powered by  Scopus

SCImago Journal & Country Rank

Recent Articles


Not Available